Cargando…

Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma

BACKGROUND: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite o...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yuanwei, Luo, Weihao, Hu, Zheng, Li, Jia, Li, Xiaojie, Cao, Huiqiu, Li, Jun, Wen, Bo, Zhang, Jian, Cheng, Hao, Guo, Wangyuan, Tan, Tan, Luo, Dixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779195/
https://www.ncbi.nlm.nih.gov/pubmed/26949513
http://dx.doi.org/10.1186/s13578-016-0082-x
_version_ 1782419592205828096
author Guo, Yuanwei
Luo, Weihao
Hu, Zheng
Li, Jia
Li, Xiaojie
Cao, Huiqiu
Li, Jun
Wen, Bo
Zhang, Jian
Cheng, Hao
Guo, Wangyuan
Tan, Tan
Luo, Dixian
author_facet Guo, Yuanwei
Luo, Weihao
Hu, Zheng
Li, Jia
Li, Xiaojie
Cao, Huiqiu
Li, Jun
Wen, Bo
Zhang, Jian
Cheng, Hao
Guo, Wangyuan
Tan, Tan
Luo, Dixian
author_sort Guo, Yuanwei
collection PubMed
description BACKGROUND: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite of great innovations in radiation and chemotherapy treatments. Highly sensitive and specific prognostic biomarkers are eager for NPC clinical diagnosis. To find specific target molecules is very important for individualized treatment. Aldo–keto reductase B10 (AKR1B10) is closely related to tumorigenesis and tumor development, and however, its expression level in NPC tissues is not clear. RESULTS: AKR1B10 expression levels were validated in benign, para-cancerous nasopharyngeal and NPC tissues by immunohistochemical evaluation. AKR1B10 was positively expressed in 42 (82.4 %) of 51 benign specimens, and 235 (98.7 %) of 238 para-carcinoma specimens. This percentage was significantly higher than 44.5 % (133/299) in nasopharyngeal carcinoma tissue (p < 0.01). AKR1B10 mRNA quantitative levels detected by real-time quantitative RT-PCR in 90 NPC tissue samples (0.10 ± 0.21) were significantly lower than that in 15 benign tissue samples (1.03 ± 1.12) (p < 0.01). AKR1B10 expression levels in NPC were correlated negatively with T-classification, lymph node metastasis (p < 0.05). We established nasopharyngeal cancer monoclonal cells CNE-2/AKR1B10 with AKR1B10 stable expression and CNE-2/vector cells without AKR1B10 expression by using a modified lentivirus-mediated method, and found that AKR1B10 inhibited the proliferation of CNE-2/AKR1B10 cells by using MTT assay and flow cytometry, and cell migration by in vitro scratch test. CONCLUSION: Taken together, our data suggest that low expression of AKR1B10 is an independent prognostic indicator in nasopharyngeal carcinoma, and that AKR1B10 may be involved in regulating the proliferation and migration of nasopharyngeal cancer cells.
format Online
Article
Text
id pubmed-4779195
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47791952016-03-06 Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma Guo, Yuanwei Luo, Weihao Hu, Zheng Li, Jia Li, Xiaojie Cao, Huiqiu Li, Jun Wen, Bo Zhang, Jian Cheng, Hao Guo, Wangyuan Tan, Tan Luo, Dixian Cell Biosci Research BACKGROUND: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite of great innovations in radiation and chemotherapy treatments. Highly sensitive and specific prognostic biomarkers are eager for NPC clinical diagnosis. To find specific target molecules is very important for individualized treatment. Aldo–keto reductase B10 (AKR1B10) is closely related to tumorigenesis and tumor development, and however, its expression level in NPC tissues is not clear. RESULTS: AKR1B10 expression levels were validated in benign, para-cancerous nasopharyngeal and NPC tissues by immunohistochemical evaluation. AKR1B10 was positively expressed in 42 (82.4 %) of 51 benign specimens, and 235 (98.7 %) of 238 para-carcinoma specimens. This percentage was significantly higher than 44.5 % (133/299) in nasopharyngeal carcinoma tissue (p < 0.01). AKR1B10 mRNA quantitative levels detected by real-time quantitative RT-PCR in 90 NPC tissue samples (0.10 ± 0.21) were significantly lower than that in 15 benign tissue samples (1.03 ± 1.12) (p < 0.01). AKR1B10 expression levels in NPC were correlated negatively with T-classification, lymph node metastasis (p < 0.05). We established nasopharyngeal cancer monoclonal cells CNE-2/AKR1B10 with AKR1B10 stable expression and CNE-2/vector cells without AKR1B10 expression by using a modified lentivirus-mediated method, and found that AKR1B10 inhibited the proliferation of CNE-2/AKR1B10 cells by using MTT assay and flow cytometry, and cell migration by in vitro scratch test. CONCLUSION: Taken together, our data suggest that low expression of AKR1B10 is an independent prognostic indicator in nasopharyngeal carcinoma, and that AKR1B10 may be involved in regulating the proliferation and migration of nasopharyngeal cancer cells. BioMed Central 2016-03-05 /pmc/articles/PMC4779195/ /pubmed/26949513 http://dx.doi.org/10.1186/s13578-016-0082-x Text en © Guo et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Guo, Yuanwei
Luo, Weihao
Hu, Zheng
Li, Jia
Li, Xiaojie
Cao, Huiqiu
Li, Jun
Wen, Bo
Zhang, Jian
Cheng, Hao
Guo, Wangyuan
Tan, Tan
Luo, Dixian
Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
title Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
title_full Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
title_fullStr Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
title_full_unstemmed Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
title_short Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
title_sort low expression of aldo–keto reductase 1b10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779195/
https://www.ncbi.nlm.nih.gov/pubmed/26949513
http://dx.doi.org/10.1186/s13578-016-0082-x
work_keys_str_mv AT guoyuanwei lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT luoweihao lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT huzheng lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT lijia lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT lixiaojie lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT caohuiqiu lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT lijun lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT wenbo lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT zhangjian lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT chenghao lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT guowangyuan lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT tantan lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma
AT luodixian lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma